loadpatents
Patent applications and USPTO patent grants for Grynspan; Frida.The latest application filed is for "treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells".
Patent | Date |
---|---|
Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells Grant 11,413,311 - Marom , et al. August 16, 2 | 2022-08-16 |
Treatment Of Inflammatory Bowel Disease With Long Acting Glatiramer And Adipose-derived Stem Cells App 20210220428 - MAROM; Ehud ;   et al. | 2021-07-22 |
Treatment Of Multiple Sclerosis With Adipose-derived Stem Cells App 20200188439 - MAROM; Ehud ;   et al. | 2020-06-18 |
Treatment Of Multiple Sclerosis With Long Acting Glatiramer And Adipose-derived Stem Cells App 20200147141 - MAROM; Ehud ;   et al. | 2020-05-14 |
Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs App 20070082397 - Hasson; Arik ;   et al. | 2007-04-12 |
Methods for ex-vivo expanding stem/progenitor cells App 20060205071 - Hasson; Arik ;   et al. | 2006-09-14 |
Expansion of renewable stem cell populations using modulators of PI 3-kinase App 20050054103 - Peled, Tony ;   et al. | 2005-03-10 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.